Data: Patients for Affordable Drugs.; Chart: Baidi Wang/Axios
Two blood thinners that Medicare spent a collective $46 billion on between 2015 and 2020 have more than doubled their list prices since entering the market, according to a new analysis by Patients for Affordable Drugs.
Why it matters: List prices don't reflect the rebates negotiated between drug manufacturers and payers, but they are often used to determine Medicare Part D cost sharing — meaning as prices go up, patients pay more out of pocket.
